Roledumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | RHD |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Roledumab is a monoclonal antibody. It binds to RHD, the Rhesus factor antigen.[1][2]
It is currently at Phase III trials for Rh disease.
References
[edit]- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
- ^ Kaplon H, Reichert JM (2018). "Antibodies to watch in 2018". mAbs. 10 (2): 183–203. doi:10.1080/19420862.2018.1415671. PMC 5825203. PMID 29300693.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |